Investigational drug · Phase 2
Ofirnoflast
Also called: HT-6184
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myelodysplastic Syndromes, Anemia, Myelodysplastic Syndrome.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "Ofirnoflast"
First trial start
2023
Dec 9, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ofirnoflast", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myelodysplastic Syndromes
- Anemia
- Myelodysplastic Syndrome
- Anemia in Myelodysplastic Syndromes
Approved drugs for the same conditions: Myelodysplastic syndromes · Anemia · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Ofirnoflast" as an intervention, largest first.
- A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell TransfusionsNot yet recruiting
Halia Therapeutics, Inc.Industry
NCT07738510 · 70 participants (planned) · Start Nov 2026 · Primary completion Oct 2028
Drug: Ofirnoflast · For: Myelodysplastic Syndromes; Anemia
Sites: Cleveland, Ohio
Halia Therapeutics, Inc.Industry
NCT07052006 · 37 participants · Start Dec 9, 2023 · Primary completion Jan 8, 2026
Drug: HT-6184 · For: Myelodysplastic Syndrome; Anemia in Myelodysplastic Syndromes
Sites: Ahmedabad, India; Kannur, India; Visakhapatnam, India · 10 sites in all
Halia Therapeutics, Inc.Industry
NCT07172867 · 0 participants · Start Jan 6, 2026 · Primary completion Jan 23, 2026
Drug: HT-6184; HT-6184 Matching Placebo and 1 more · For: Diabetes Mellitus, Type 2; Obesity
Sites: Abu Dhabi, United Arab Emirates
Newest research
PubMed records naming it or its code names, newest first.
- Immunopharmacological reprogramming of innate immune memory in Alzheimer's disease: From microglial priming to therapeutic resilience.
Abdelaziz AM, Eladawy RM · Biochem Pharmacol 2026
- Ofirnoflast: a first-in-class NEK7-targeted inhibitor of the NLRP3 inflammasome.
Mollard A, Bursey D, Burnett W, et al. · J Drug Target 2026
Also in development for Myelodysplastic Syndromes
- AND017Phase 36 trials
Kind Pharmaceuticals LLC · Anemia Due to Chronic Kidney Disease, β -Thalassemia, Cancer-Related Anemia
- ElriterceptTAK-226, KER-050Phase 36 trials
Takeda · Myelodysplastic Syndromes, Myelofibrosis, Anemia
- BL-M11D1Phase 32 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Acute Myeloid Leukemia, Myelodysplastic Syndromes
- RoxadustatFG-4592, ASP1517Phase 32 trials
Astellas · Chronic Kidney Disease, Renal Anemia, Myelodysplastic Syndromes
- ASTX030cedazuridine + azacitidinePhase 31 trial
Taiho Oncology, Inc. · Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm
- RimiducidAP1903Phase 23 trials
Bellicum Pharmaceuticals · Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Leukemia, Acute Myeloid (AML), Child
- bexmarilimabFP-1305Phase 22 trials
Faron Pharmaceuticals Ltd · Higher Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- DISC-0974Phase 22 trials
Disc Medicine, Inc · Anemia, Inflammatory Bowel Disease (IBD), Inflammatory Bowel Disease (IBD); Anemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.